Since 1999, the number of transplants has dramatically increased for acute leukemia, myelodysplastic disease and lymphoma, while transplants for chronic myelogenous leukemia have declined. 

See bar graph illustration.

CML patients today are higher risk because they primarily represent patients who failed to improve on imatinib therapy.